A Phase 3 interventional study of IGSC 20% infusion in Primary Immunodeficiency Disease, sponsored by Takeda. Completed at 8 sites in Japan. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 9 in phase 3, and was the 15th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study.
The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has completed or is about to complete Takeda Clinical Study TAK-664-3001.
A participant is considered to have completed Study TAK-664-3001 successfully if they fulfill the following criterion: Completed Epoch 2, in which IGSC, 20% is administered weekly (completion of Epoch 3, in which IGSC, 20% is administered biweekly, is not mandatory for participation in TAK-664-3002 study).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who completed Epoch 2 of core study TAK-664-3001 (NCT04346108), received between 50 to 200 mg/kg of Immune globulin subcutaneous (IGSC) infusion, 20% infusion once a week (Epoch 2 regimen) and 100 to 400 mg/kg of IGSC infusion, 20% biweekly (Epoch 3 regimen) until the study drug becomes commercially available.
Biological: IGSC 20% infusion
IGSC 20% infusion,
Also known as: Immune Globulin Infusion (Human)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Number of Participants With Drug-related and Non-related TEAEs
TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). Any TEAE that was recorded by the investigator as "probably related" or "possibly related" to study drug was considered as study drug related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE.
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Number of Participants With Severe, Local and Systemic TEAEs
A severe TEAE was an AE that caused considerable interference with the participant's usual activities. Local TEAEs were defined as AEs that were included in the MedDRA Higher Level Group Term "administration site reactions" or contained the phrase "injection site" or "infusion site". Systemic TEAEs were defined as AEs that were not included in the Medical Dictionary for Regulatory Activities (MedDRA) Higher Level Group Term "administration site reactions" and did not contain the phrase "injection site" or "infusion site".
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Number of Participants With TEAEs Leading to Premature Discontinuation From Study and Infusion-associated TEAEs
Infusion associated TEAEs were defined as any TEAE that began during study drug infusion or within 72 hours of completion of study drug infusion. TEAEs leading to premature discontinuation from study and infusion-associated TEAEs were reported.
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Serum Trough Levels of Total Immune Globulin G (IgG) and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Weekly Administration of IGSC, 20%
Serum trough levels of total IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.
Time frame: At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)
Serum Trough Levels of IgG and IgG1, IgG2, IgG3, IgG4 Antibodies Subclasses Following Biweekly Administration of IGSC, 20%
Serum trough levels of IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.
Time frame: At end of treatment in the current extension study TAK-664-3002 (i.e. 3 years)
Annual Rate of Validated Acute Serious Bacterial Infections (ASBI)
The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Annual Rate of All Infections
The annual rate of infections was calculated as the mean number of infections per participant per year. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection
Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Number of Days Participants on Antibiotics
Number of days on antibiotics was defined as the number of days those antibiotics were taken as concomitant medications and was standardized to per year (365.25 days). Number of days participants on antibiotics were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Number of Hospitalizations Due to Illness or Infection
Number of hospitalizations were standardized to per year (365.25 days). Hospitalizations were measured by asking participants to report the number of nights they have stayed overnight in the hospital during the year, for something related to their own health. Number of hospitalizations due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Length of Hospital Stay Due to Illness or Infection
Length of hospital stay per stay was standardized to per year (365.25 days). Number of days due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Number of Acute Physician Visits Due to Illness/Infection
Number of acute physician visits is standardized to per year (365.25 days). Number of acute (urgent or unscheduled) physician visits due to illness/infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
Time frame: From first dose of study drug in core study TAK-664-3001 up to end of current extension study TAK-664-3002 (up to approximately 4.5 years)
Number of Participants With Their Response for Treatment Preference Questionnaire
Treatment preference questionnaire is a self-administered questionnaire developed to assess participant's preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. For First question "Before participation in the trial(s), where did you receive your immunoglobulin therapy" participants were allowed to select multiple answers for options ("At the hospital"; "At home"; "Other") for their treatment. As a result, the sum of responders in the arm "IGSC, 20%: \>=14 Years" for the first question were higher than the total number of participants analyzed in the category.
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Number of Participants With Tolerability Events Related to the Infusion of Study Drug
An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to a TEAE related to study drug infusion. A tolerability event was considered to have occurred if an infusion was not tolerable.
Time frame: From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose
Participants took part in the study at 8 investigative sites in Japan from 27 April 2021 to 25 April 2024.
| Milestone | IGSC, 20% |
|---|---|
| Started | 12 |
| Completed | 10 |
| Not completed | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Other | 1 |
TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). A serious TEAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
| Participants | IGSC, 20% |
|---|---|
| TEAEs | 12 |
| Serious TEAEs | 3 |
| Non-serious TEAEs | 12 |
TEAEs were defined as adverse events (AEs) with onset after date-time of first dose of study drug (intravenous immunoglobulin \[IGIV\] or IGSC), or medical conditions present prior to the start of study drug (IGIV or IGSC) but increased in severity or relationship after date-time of first dose of study drug (IGIV or IGSC). Any TEAE that was recorded by the investigator as "probably related" or "possibly related" to study drug was considered as study drug related AE, and any AE recorded as "unlikely related" or "not related" was considered as unrelated AE.
| Participants | IGSC, 20% |
|---|---|
| Drug-related TEAEs | 9 |
| Non-related TEAEs | 12 |
A severe TEAE was an AE that caused considerable interference with the participant's usual activities. Local TEAEs were defined as AEs that were included in the MedDRA Higher Level Group Term "administration site reactions" or contained the phrase "injection site" or "infusion site". Systemic TEAEs were defined as AEs that were not included in the Medical Dictionary for Regulatory Activities (MedDRA) Higher Level Group Term "administration site reactions" and did not contain the phrase "injection site" or "infusion site".
| Participants | IGSC, 20% |
|---|---|
| Severe TEAEs | 3 |
| Local TEAEs | 8 |
| Systemic TEAEs | 12 |
Infusion associated TEAEs were defined as any TEAE that began during study drug infusion or within 72 hours of completion of study drug infusion. TEAEs leading to premature discontinuation from study and infusion-associated TEAEs were reported.
| Participants | IGSC, 20% |
|---|---|
| TEAEs Leading to Premature Discontinuation | 0 |
| Infusion-associated TEAEs | 12 |
Serum trough levels of total IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.
| grams per liter (g/L) | IGSC, 20% |
|---|---|
| IgG 1 | 6.14 (4.25 to 8.87) |
| IgG 2 | 3.52 (2.35 to 5.28) |
| IgG 3 | NA (NA to NA) |
| IgG 4 | 0.305 (0.165 to 0.567) |
| IgG Total | 11.0 (7.29 to 16.5) |
Serum trough levels of IgG and IgG1, IgG2, IgG3, IgG4 antibodies subclasses were determined by using standard assay methods.
| g/L | IGSC, 20% |
|---|---|
| IgG 1 | 5.36 (4.55 to 6.33) |
| IgG 2 | 3.42 (3.03 to 3.86) |
| IgG 3 | NA (NA to NA) |
| IgG 4 | 0.250 (0.219 to 0.284) |
| IgG Total | 8.98 (7.78 to 10.4) |
The ASBI rate was calculated as the mean number of acute serious bacterial infections per participants per year. Annual rate of validated acute serious bacterial infections per participant was assessed. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| infections per year | IGSC, 20% |
|---|---|
| Annual Rate of Validated Acute Serious Bacterial Infections (ASBI) | 0.00 ± 0.000 |
The annual rate of infections was calculated as the mean number of infections per participant per year. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| infections per year | IGSC, 20% |
|---|---|
| Annual Rate of All Infections | 1.42 ± 1.119 |
Number of days not able to attend school or work to perform normal daily activities due to illness/infection are standardized per year (365.25 days). Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| days | IGSC, 20% |
|---|---|
| Number of Days Participants Not Able to Attend School or Work to Perform Normal Daily Activities Due to Illness/Infection | 1.91 (0.0 to 31.9) |
Number of days on antibiotics was defined as the number of days those antibiotics were taken as concomitant medications and was standardized to per year (365.25 days). Number of days participants on antibiotics were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| days | IGSC, 20% |
|---|---|
| Number of Days Participants on Antibiotics | 2.55 (0.0 to 57.8) |
Number of hospitalizations were standardized to per year (365.25 days). Hospitalizations were measured by asking participants to report the number of nights they have stayed overnight in the hospital during the year, for something related to their own health. Number of hospitalizations due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| hospitalization | IGSC, 20% |
|---|---|
| Number of Hospitalizations Due to Illness or Infection | 0.21 ± 0.370 |
Length of hospital stay per stay was standardized to per year (365.25 days). Number of days due to illness or infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| days | IGSC, 20% |
|---|---|
| Length of Hospital Stay Due to Illness or Infection | 0.00 (0.0 to 3.9) |
Number of acute physician visits is standardized to per year (365.25 days). Number of acute (urgent or unscheduled) physician visits due to illness/infection were reported. Reported timeframe included timeframe of core study TAK-664-3001 (NCT04346108) (Max approximately 1.5 year) and of current extension study (Max approximately 3 years) as data of this outcome measure was collected from first dose of core study to end of current extension study and the data is presented for participants who entered in current study from core study as per plan.
| visits per year | IGSC, 20% |
|---|---|
| Number of Acute Physician Visits Due to Illness/Infection | 2.66 ± 2.652 |
Treatment preference questionnaire is a self-administered questionnaire developed to assess participant's preference towards the administration of new IGSC therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the IGSC treatment. For First question "Before participation in the trial(s), where did you receive your immunoglobulin therapy" participants were allowed to select multiple answers for options ("At the hospital"; "At home"; "Other") for their treatment. As a result, the sum of responders in the arm "IGSC, 20%: \>=14 Years" for the first question were higher than the total number of participants analyzed in the category.
| Participants | IGSC, 20%: 2-13 Years | IGSC, 20%: >=14 Years |
|---|---|---|
| Before participation in the trial(s), where did you receive your immunoglobulin therapy: At home | 0 | 0 |
| Before participation in trial(s), where did you receive your immunoglobulin therapy: At hospital | 3 | 8 |
| Before participation in the trial(s), where did you receive your immunoglobulin therapy: Other | 0 | 4 |
| Where do you Prefer to Receive Your Immunoglobulin Therapy: At Hospital | 1 | 1 |
| Where do you Prefer to Receive Your Immunoglobulin Therapy: At Home | 0 | 6 |
| Where do you Prefer to Receive Your Immunoglobulin Therapy: No Preference | 2 | 2 |
| The Frequency of Administration: Like very much | 1 | 1 |
| The Frequency of Administration: Like | 1 | 4 |
| The Frequency of Administration: No preference | 1 | 3 |
| The Frequency of Administration: Dislike | 0 | 1 |
| The Frequency of Administration: Dislike very much | 0 | 0 |
| The number of needlesticks per month: Like very much | 1 | 1 |
| The number of needlesticks per month: Like | 1 | 5 |
| The number of needlesticks per month: No preference | 1 | 2 |
| The number of needlesticks per month: Dislike | 0 | 1 |
| The number of needlesticks per month: Dislike very much | 0 | 0 |
| Total time spent for treatment per month: Like very much | 0 | 3 |
| Total time spent for treatment per month: Like | 1 | 2 |
| Total time spent for treatment per month: No preference | 1 | 1 |
| Total time spent for treatment per month: Dislike | 1 | 3 |
| Total time spent for treatment per month: Dislike very much | 0 | 0 |
| The ease of administration: Like very much | 1 | 3 |
| The ease of administration: Like | 2 | 4 |
| The ease of administration: No preference | 0 | 1 |
| The ease of administration: Dislike | 0 | 1 |
| The ease of administration: Dislike very much | 0 | 0 |
| The potential to self-administer: Like very much | 2 | 5 |
| The potential to self-administer: Like | 0 | 4 |
| The potential to self-administer: No preference | 0 | 0 |
| The potential to self-administer: Dislike | 0 | 0 |
| The potential to self-administer: Dislike very much | 1 | 0 |
| Ability to fit treatment into schedule: Like very much | 1 | 5 |
| Ability to fit treatment into schedule: Like | 2 | 1 |
| Ability to fit treatment into schedule: No preference | 0 | 3 |
| Ability to fit treatment into schedule: Dislike | 0 | 0 |
| Ability to fit treatment into schedule: Dislike very much | 0 | 0 |
| The overall convenience: Like very much | 0 | 4 |
| The overall convenience: Like | 3 | 3 |
| The overall convenience: No preference | 0 | 2 |
| The overall convenience: Dislike | 0 | 0 |
| The overall convenience: Dislike very much | 0 | 0 |
| The amount of time administration takes: Like very much | 0 | 1 |
| The amount of time administration takes: Like | 1 | 5 |
| The amount of time administration takes: No preference | 1 | 1 |
| The amount of time administration takes: Dislike | 1 | 2 |
| The amount of time administration takes: Dislike very much | 0 | 0 |
| Complexity of administration: Like very much | 0 | 2 |
| Complexity of administration process: Like | 3 | 4 |
| Complexity of administration: No preference | 0 | 2 |
| Complexity of administration: Dislike | 0 | 1 |
| Complexity of administration: Dislike very much | 0 | 0 |
| Ability to self-administer: Like very much | 2 | 6 |
| Ability to self-administer: Like | 1 | 3 |
| Ability to self-administer: No preference | 0 | 0 |
| Ability to self-administer: Dislike very much | 0 | 0 |
| Ability to self-administer: Dislike | 0 | 0 |
| Choose to continue receiving IGSC: Yes | 3 | 7 |
| Choose to continue receiving IGSC: No | 0 | 2 |
| Factor influence decision: Two way needle, to see more variation in volume of chemical solution. | 0 | 1 |
| Factor influenced decision: Can be self-administered at home | 1 | 0 |
| Factor influenced decision: Easy administration method, easy to use | 0 | 1 |
| Factor influenced decision: Feel relieved | 0 | 1 |
| Factor influenced decision: Fewer side effects. IgG levels stabilized and became easier | 0 | 1 |
| Factor influence decision:.Take time to prepare, clean up, for area affected by needle to recover. | 0 | 1 |
| Factor influenced decision: Less susceptible to infections. Atopic dermatitis improved | 1 | 0 |
| Factor influenced decision: No answer | 1 | 0 |
| Factor influenced decision: No more coughing | 0 | 1 |
| Factor influenced decision: The values are stable | 0 | 1 |
| Factor influenced decision: Time is short | 0 | 1 |
| Factor influence decision: There were no major side effects and stable medical condition | 0 | 1 |
An infusion was considered tolerable if the infusion rate was not reduced, or the infusion was not interrupted or stopped, due to a TEAE related to study drug infusion. A tolerability event was considered to have occurred if an infusion was not tolerable.
| Participants | IGSC, 20% |
|---|---|
| Infusion rate was reduced | 1 |
| Infusion was interrupted | 4 |
| Infusion was stopped | 1 |
Collected over From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IGSC, 20% | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Event | IGSC, 20% |
|---|---|
| Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/12 |
| Rhegmatogenous retinal detachmentEye disorders | 1/12 |
| Event | IGSC, 20% |
|---|---|
| HeadacheNervous system disorders | 6/12 |
| COVID-19Infections and infestations | 5/12 |
| PyrexiaGeneral disorders | 5/12 |
| Vaccination complicationInjury, poisoning and procedural complications | 5/12 |
| Injection site swellingGeneral disorders | 4/12 |
| SinusitisInfections and infestations | 4/12 |
| Dental cariesGastrointestinal disorders | 3/12 |
| GastroenteritisInfections and infestations | 3/12 |
| Injection site erythemaGeneral disorders | 3/12 |
| Injection site painGeneral disorders | 3/12 |
All-Treated Set consisted of all enrolled participants who received IGSC, 20% administration at least once in this study.
| Age, Continuous(years) | IGSC, 20% |
|---|---|
| Mean | 36.0 ± 21.68 |
| Sex: Female, Male(Participants) | IGSC, 20% |
|---|---|
| Female | 7 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | IGSC, 20% |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | IGSC, 20% |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 12 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).
Ran from Apr 2021 to primary completion in Apr 2024, 35 months.
Results were first posted in Jan 2025, 8 months after primary completion.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins
Primary Immunodeficiency Diseases →